This is because BRAF inhibitors are supposed to modulate the tumor immune microenvironment by increasing interferon-gamma production on intratumoral CD4+ T lymphocytes and increasing CD8+ TILs [49,50]. This evidence concerns the gene CD4 and neoplasm.